Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options

Epilepsy is a common chronic neurological disease. The problems of people with epilepsy go well beyond epileptic seizures. Comorbidities in epilepsy are very common and often cause more problems to the patients than the seizures themselves. Although seizures are the most prominent clinical presentat...

Full description

Bibliographic Details
Main Authors: N. V. Pizova, A. V. Pizov
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-08-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/6268
_version_ 1797841690926514176
author N. V. Pizova
A. V. Pizov
author_facet N. V. Pizova
A. V. Pizov
author_sort N. V. Pizova
collection DOAJ
description Epilepsy is a common chronic neurological disease. The problems of people with epilepsy go well beyond epileptic seizures. Comorbidities in epilepsy are very common and often cause more problems to the patients than the seizures themselves. Although seizures are the most prominent clinical presentation of epilepsy, people with epilepsy are exposed to risk of not only seizures, but also of many health problems. Both children and adults with epilepsy often complain of memory impairment. It is commonly believed that cognitive dysfunction in epilepsy is multifactorial. The components that deteriorate cognitive functions include active seizures and especially generalized tonic-clonic seizures, traumatic brain injuries, structural epilepsy, and drug therapy. Cognitive dysfunction is very often present as far back as during the onset of epilepsy. The cognitive dysfunction detected in patients with epilepsy depend on the localization of the epileptic focus, the frequency and type of epileptic seizures, and changes in the interictal electroencephalogram. Seizures can be controlled with antiepileptic drugs in most patients with epilepsy. Therapy of cognitive dysfunction in patients with epilepsy presents significant difficulties, as there is no evidence of the efficacy of various drugs in cognitive disorders. The article presents a new Russian antiepileptic drug based on phenosanic acid as part of combination therapy in patients with partial epileptic seizures with or without secondary generalization, which can improve cognitive functions in patients with epilepsy.
first_indexed 2024-04-09T16:35:24Z
format Article
id doaj.art-5b8de0d40c7d4022a61e3dd6a5844420
institution Directory Open Access Journal
issn 2079-701X
2658-5790
language Russian
last_indexed 2024-04-09T16:35:24Z
publishDate 2021-08-01
publisher Remedium Group LLC
record_format Article
series Медицинский совет
spelling doaj.art-5b8de0d40c7d4022a61e3dd6a58444202023-04-23T06:56:56ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-08-01010869310.21518/2079-701X-2021-10-86-935663Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic optionsN. V. Pizova0A. V. Pizov1Yaroslavl State Medical UniversityYaroslavl State Pedagogical University named after K.D. UshinskyEpilepsy is a common chronic neurological disease. The problems of people with epilepsy go well beyond epileptic seizures. Comorbidities in epilepsy are very common and often cause more problems to the patients than the seizures themselves. Although seizures are the most prominent clinical presentation of epilepsy, people with epilepsy are exposed to risk of not only seizures, but also of many health problems. Both children and adults with epilepsy often complain of memory impairment. It is commonly believed that cognitive dysfunction in epilepsy is multifactorial. The components that deteriorate cognitive functions include active seizures and especially generalized tonic-clonic seizures, traumatic brain injuries, structural epilepsy, and drug therapy. Cognitive dysfunction is very often present as far back as during the onset of epilepsy. The cognitive dysfunction detected in patients with epilepsy depend on the localization of the epileptic focus, the frequency and type of epileptic seizures, and changes in the interictal electroencephalogram. Seizures can be controlled with antiepileptic drugs in most patients with epilepsy. Therapy of cognitive dysfunction in patients with epilepsy presents significant difficulties, as there is no evidence of the efficacy of various drugs in cognitive disorders. The article presents a new Russian antiepileptic drug based on phenosanic acid as part of combination therapy in patients with partial epileptic seizures with or without secondary generalization, which can improve cognitive functions in patients with epilepsy.https://www.med-sovet.pro/jour/article/view/6268epilepsycomorbiditiescognitive impairmenttherapyphenosanic acid
spellingShingle N. V. Pizova
A. V. Pizov
Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
Медицинский совет
epilepsy
comorbidities
cognitive impairment
therapy
phenosanic acid
title Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
title_full Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
title_fullStr Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
title_full_unstemmed Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
title_short Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
title_sort certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
topic epilepsy
comorbidities
cognitive impairment
therapy
phenosanic acid
url https://www.med-sovet.pro/jour/article/view/6268
work_keys_str_mv AT nvpizova certainriskfactorsforthedevelopmentofcognitiveimpairmentinpersonswithepilepsyandnewtherapeuticoptions
AT avpizov certainriskfactorsforthedevelopmentofcognitiveimpairmentinpersonswithepilepsyandnewtherapeuticoptions